RESEARCH PAPERS – Treatment

Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management

Castells M, Butterfield J. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. J Allergy Clin Immunol Pract. 2019;7(4):1097-1106. doi:10.1016/j.jaip.2019.02.002

19.09.2021

Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome.

Jagdis A, Vadas P. Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome. Ann Allergy Asthma Immunol. 2014;113(1):115-116. doi:10.1016/j.anai.2014.05.001

19.09.2021

Timing of response and long term efficacy of Omalizumab in non-clonal mast cell activation syndrome: A case series.

Caminati M, Olivieri E, Nalin F, et al. Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series. Eur J Intern Med. 2020;71:104-106. doi:10.1016/j.ejim.2019.11.010

19.09.2021

Mast Cell disorders and idiopathic anaphylaxis: Evaluation and Management

Khalid MB, Lieberman P. Mast cell disorders and idiopathic anaphylaxis: Evaluation and management. Allergy Asthma Proc. 2020;41(2):90-98. doi:10.2500/aap.2020.41.190023

18.09.2021

Successful treatment of mast cell activation syndrome with sunitinib

Afrin LB, Cichocki FM, Patel K, Molderings GJ. Successful treatment of mast cell activation syndrome with sunitinib. Eur J Haematol. 2015;95(6):595-597. doi:10.1111/ejh.12606

17.09.2021

Successful targeted treatment of mast cell activation syndrome with tofacitinib

Afrin LB, Fox RW, Zito SL, Choe L, Glover SC. Successful targeted treatment of mast cell activation syndrome with tofacitinib. Eur J Haematol. 2017;99(2):190-193. doi:10.1111/ejh.12893

17.09.2021

Generalized Pruritus Relieved by NSAIDs in the Setting of Mast Cell Activation Syndrome

Kesterson K, Nahmias Z, Brestoff JR, Bodet ND, Kau A, Kim BS. Generalized pruritus relieved by NSAIDs in the setting of mast cell activation syndrome. J Allergy Clin Immunol Pract. 2018;6(6):2130-2131. doi:10.1016/j.jaip.2018.03.002

17.09.2021

Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases

Espinosa E, Valitutti S, Laroche M, et al. Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases. Clin Immunol. 2018;194:75-79. doi:10.1016/j.clim.2018.07.004

17.09.2021

Successful treatment of idiopathic mast cell activation syndrome with low-dose Omalizumab

Berry R, Hollingsworth P, Lucas M. Successful treatment of idiopathic mast cell activation syndrome with low-dose Omalizumab. Clin Transl Immunology. 2019;8(10):e01075. Published 2019 Sep 30. doi:10.1002/cti2.1075

17.09.2021

Utility of hydroxyurea in mast cell activation syndrome

Afrin LB. Utility of hydroxyurea in mast cell activation syndrome. Exp Hematol Oncol. 2013;2(1):28. Published 2013 Oct 9. doi:10.1186/2162-3619-2-28

17.09.2021

Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment

Weinstock LB, Brook JB, Myers TL, Goodman B. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Rep. 2018;2018:bcr2017221405. Published 2018 Jan 11. doi:10.1136/bcr-2017-221405

15.09.2021

Selective Response to Omalizumab in a Patient With Concomitant ncMCASand POTS: What Does it Teach us About the Underlying Disease?

Kacar M, Denman S, Savic S. Selective Response to Omalizumab in a Patient With Concomitant ncMCAS and POTS: What Does it Teach us About the Underlying Disease?. J Investig Allergol Clin Immunol. 2018;28(4):261-263. doi:10.18176/jiaci.0251

15.09.2021

Management of a Parturient with Mast Cell Activation Syndrome: An Anesthesiologist’s Experience

Kumaraswami, Sangeeta & Farkas, Gabriel. (2018). Management of a Parturient with Mast Cell Activation Syndrome: An Anesthesiologist’s Experience. Case Reports in Anesthesiology. 2018. 1-5. 10.1155/2018/8920921.

15.09.2021

Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: A case report

Malik F, Ali N, Jafri SIM, et al. Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report. J Med Case Rep. 2017;11(1):119. Published 2017 Apr 24. doi:10.1186/s13256-017-1278-3

15.09.2021

Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes

González-de-Olano D, Matito A, Orfao A, Escribano L. Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes. F1000Res. 2016;5:2666. Published 2016 Nov 14. doi:10.12688/f1000research.9565.1

15.09.2021

21st Century Mast Cell Stabilisers

Finn DF, Walsh JJ. Twenty-first century mast cell stabilizers. Br J Pharmacol. 2013;170(1):23-37. doi:10.1111/bph.12138

15.09.2021

A Practical Guide for Treatment of Pain in Patients with Systemic Mast Cell Activation Disease

Wirz S, Molderings GJ. A Practical Guide for Treatment of Pain in Patients with Systemic Mast Cell Activation Disease. Pain Physician. 2017 Sep;20(6):E849-E861.

01.09.2017

Pharmacological treatment options for mast cell activation

Molderings GJ, Haenisch B, Brettner S et al. Pharmacological treatment options for mast cell activation. Naunyn Schmiedebergs Arch Pharmacol. 2016 Jul;389(7):671-94

01.04.2016

Utility of Continuous Diphenhydramine Infusion in Severe Mast Cell Activation Syndrome

Lawrence B Afrin; Utility of Continuous Diphenhydramine Infusion in Severe Mast Cell Activation Syndrome; Blood 2015 126:5194

01.11.2015

H1-antihistamines for primary mast cell activation syndromes: a systematic review

4 Nurmatov UB, Rhatigan E, Simons FE, Sheikh A. H1-antihistamines for primary mast cell activation syndromes: a systematic review. Allergy. 2015;70(9):1052-61.

01.07.2015

Become a friend

Sign up to become a Friend of Mast Cell Action so we can keep you up to date on our progress and on how to get involved in our latest campaigns and initiatives. Please click on Data Protection at the bottom of the page to see our Data Protection Information.

Become a friend

Donate

Mast Cell Action relies entirely on the generosity of people like you. Please make a donation now and together we can make a difference for sufferers of MCAS.

Make a donation

Close